World Anticoagulants Market

World Anticoagulants Market

This report analyzes the worldwide markets for Anticoagulants in Millions of US$. The major product segments analyzed are Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 51 companies including many key and niche players worldwide such as AstraZeneca PLC, Barr Laboratories Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, and Sanofi-Aventis. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTICOAGULANTS MCP-1205
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions And Scope Of Study I-3


II. EXECUTIVE SUMMARY

1. Worldwide Anticoagulants Market II-1
Global Market Overview II-1
Current and Future Scenario II-1
Major Markets - Products II-1
Injectable Anticoagulants - On An Up Trend II-1
Low Molecular Weight Heparins - Ruling the Roost II-1
Major Markets - Regional II-2
United States - The Largest Market II-2
Europe - The Second Largest Market II-2

2. Industry Overview II-3
The Pharmaceuticals Industry II-3
Industry Framework II-3
Regulatory Price Controls - Present and Future II-3
Consolidations Driving the Industry II-4
Patent Expiries Giving Way to Generic Drugs II-4
Anticoagulants Sector II-4
A Snapshot of Available Therapies II-4
An Insight into Currently Available Antithrombotic Drugs II-5
Weaknesses of Available Therapies II-5
Forces Driving the Market II-6
Oral Anticoagulants Market II-6
Injectable Anticoagulants Market II-6
Heparin Market II-6
LMWH Market II-7

3. Market Dynamics II-8
Drug Advancements Drive Anticoagulant Market II-8
Niche Markets - The New Target for Drug Makers II-8
An Opportunity to Grow Further II-8
Geriatric Patients - At High Risk of Blood Clots II-8
Improved Anticoagulant Agents for Children Group II-9
Growing Demand for Self-Testing II-9
LMWHs Eases Outpatient Management II-9
Concern Over Underutilization of Warfarin II-9
Anticoagulants to Lose UA/AMI Markets to Antiplatelets II-10
Influx of New Drugs: Invigorates the Market II-10
Novel Heparins: Enhances Market Potential II-10
Anticoagulant Therapy During Pregnancy Improves Outcomes II-10
New Therapies: Need of the Hour II-11
Anticoagulant Therapy in IPF: Reduces Mortality Risk II-11
Failure of Exanta II-11

4. Product Overview II-12
Introduction to Anticoagulants II-12
Evolution of Anticoagulants II-12
Blood Coagulation - A Major Concern II-12
Anticoagulants Disrupts Metastatic Events II-13
The Coagulation Cascade II-13
Coagulation Factors Found in the Coagulation Cascade II-13
Precautions II-13
Side Effects II-14
Hemorrhagic Symptoms and Side Effects II-14
Impediments II-15
Potential Candidates for Anticoagulation II-15
Alternative Therapies to Anticoagulants II-15
Thrombolytics - Another Major Solution for Thrombosis II-15
Anticoagulants Drug Class II-16
Oral Anticoagulants II-16
Oral Anticoagulants Induces Calcification II-16
Warfarin II-16
Advantages and Alternatives II-16
Side Effects II-17
Limitations II-17
Coumadin II-17
Injectable Anticoagulants II-18
Heparin - The Backbone of Injectable Anticoagulants II-18
Unfractionated Heparin II-19
Advantages and Alternatives II-19
Limitations II-19
Low Molecular Weight Heparins II-20
Costs II-21
Impediments II-22
Lovenox/Clexane (enoxaparin) II-22
Approved Indications for Lovenox: II-22
Advantages and Alternatives II-22
Fragmin (dalteparin) II-23
Approved Indications for Fragmin Use: II-23
Contradictions II-23
Precautions II-24
Fraxiparine (nadroparin) II-24
Innohep (tinzaparin) II-25
Contraindications II-25
Side Effects II-26
Other Serious Adverse Events Associated with Innohep II-26
Precautions II-26
Normiflo (ardeparin) II-27
Clivarine (reviparin) II-27
Summary of Available LMWHs II-27
Non-Heparin Injectables II-27
Arixtra (fondaparinux) II-27
Contraindications II-28
Market and Market Participants II-28
Angiomax (bivalirudin) II-28
Advantages II-29
Contraindications II-29
Side Effects II-29
Argatroban/ Novastan II-29
Side Effects II-30
Precautions II-30
Refludan (lepirudin) II-30
Orgaran (danaparoid sodium) II-30
Contraindications II-31
Side Effects II-31
Caution II-32
Precaution II-32
A Comparative Analysis of Various Direct Thrombin Inhibitors II-32
Other Anticoagulants II-32
Lithium Heparin II-32
EDTA II-33
Citrate II-33
Oxalate II-33

5. A Comparative Study of Anticoagulant Therapies II-34

A Comparative Study of Warfarin Against LMWHs II-34
A Comparative Study of LMWH Against UFH II-35
A Comparative Study of Heparin Against Angiomax II-36
A Comparative Study of Arixtra Against UFH and LMWH II-36
A Comparative Study of Angiomax Against UFH and LMWH II-36

6. Areas of Indication II-37
Indications for Anticoagulant Use II-37
Venous/DVT Thrombosis Indications II-37
Venous Thromboembolism (VTE) II-37
Deep Vein Thrombosis (DVT) II-37
Pulmonary Embolism (PE) II-39
Orthopedic (Hip or Knee Replacement) Surgery II-40
General Surgery II-41
Cancer II-42
Arterial Thrombosis Indications II-42
Arterial Thrombosis II-42
Acute Coronary Syndromes (ACS) II-43
Atrial Fibrillation (AF) II-43
Unstable Angina (UA) II-44
List of Approved Anticoagulants for Unstable Angina II-45
Myocardial Infraction (MI) II-45
Non-ST Segment Elevation MI II-45
List of Approved Anticoagulants for Non-ST Segment
Elevation Myocardial Infraction II-46
Percutaneous Transluminal Coronary Angioplasty (PTCA) II-46
List of Approved Anticoagulants for Angioplasty Procedures II-47
Heparin Induced Thrombocytopenia (HIT) Indications II-47
HIT Type I II-47
HIT Type II II-48
Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-49
Other Indications II-49
Hemodialysis II-49

7. Drug Development Pipeline II-50
Select Anticoagulants Under Pipeline II-50
Idraparinux - Sanofi-Aventis II-50
0673 - Sanofi-Aventis II-51
BIBR1048MS - Boehringer Ingelheim II-51

8. Product Introductions II-52
Boehringer Receives EU Approval for Pradaxa II-52
Sanofi-Aventis Receives Approval for Clexane® in Japan II-52
ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay II-52
Lannett Obtains US FDA Approval for Dipyridamole Tablets II-52
Kimball Introduces New Pharmacogenetic Test II-52
Roche Launches an Improved Point-of-Care Anticoagulation
Monitoring System II-53
Danish Agency Grants Approval for Anticoagulant Clinical Trials II-53
EMEA Approves ARIXTRA® of GlaxoSmithKline II-53
FDA Approves ANDAs of PLIVA II-53
FDA Approves ARIXTRA Injection of GSK II-53
Japanese Ministry Approves Arixtra of GSK II-54
Eisai Obtains FDA Approval for Fragmin II-54
Sanofi-Aventis' Lovenox® Obtains FDA Approval for Acute
Cardiac Care II-54
Zydus Cadila's Warfarin Secures Approval from US FDA II-54
Momenta Pharmaceuticals Seeks Approval for M-Enoxaparin II-55
Mitsubishi Pharma Releases Argatroban in Europe II-55
Regado Develops Anticoagulant II-55

9. Recent Industry Activity II-56
PAION Acquires CeNes Pharmaceuticals II-56
PAION Announces Acquisition of Global Rights to Trigen’s
flovagatran II-56
Biological E Collaborates with Choncept and Heparinex II-56
Bayer’s Market Expansion II-56
B. Braun Recalls Heparin Sodium Based Injection Solutions II-56
Baxter Recalls Heparin Sodium Vials II-57
Celgene Acquires Pharmion II-57
BMS Collaborates with Pfizer II-57
Medicines Company Reacquires European Rights for Angiox II-58
HemoSense and LabCorp Sign Agreement for Supply of INRatio System II-58
Sanofi-Aventis Acquires Rights for Panaldine from Daiichi II-58
Alchemia Inks Marketing Alliance with Dr Reddy’s for Heparin II-59
Inverness Announces Acquisition of HemoSense II-59
ev3, FoxHollow Complete Merger II-59
Osmetech Signs Licensing Agreement with Marshfield Clinic II-59
Mitsubishi and Tanabe Agree to Merge II-60
Artisan and A-Bio Form Alliance II-60
Archemix and Nuvelo Announces Expansion of Alliance II-60
American Capital Acquires Scientific Protein Laboratories’ One
Stop Buyout™ II-60
Bristol-Myers to Start New Facility in Massachusetts II-61
AstraZeneca Stops Development of Exanta II-61
Pfizer Enters into Agreement with BPC II-61
AstraZeneca Pacts with Targacept II-61
GlaxoSmithKline Acquires ID Biomedical II-61
Direct Capital Buys Stake in NZP II-61
Archemix and Nuvelo Stop Development of ARC183 II-61
Novartis Purchases Bristol-Myers’ US/Canadian Consumer
Medicine Operations II-61
Akers Pacts with Cardinal Health II-62

10. Focus on Select Global Players II-63
AstraZeneca PLC (UK) II-63
Barr Laboratories Inc (USA) II-63
Bristol-Myers Squibb Company (USA) II-63
Celgene Corporation (USA) II-64
GlaxoSmithKline plc (UK) II-64
Mitsubishi Tanabe Pharma Corporation (Japan) II-64
Pfizer Inc (USA) II-64
Sanofi-Aventis (France) II-65

11. Global Market Perspective II-66
Table 1: World Recent Past, Current & Future Analysis for
Anticoagulants by Geographic Region/Country - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-66

Table 2: World Long-term Projections for Anticoagulants by
Geographic Region/Country - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-67

Table 3: World 10-Year Perspective for Anticoagulants by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-68

Table 4: World Recent Past, Current & Future Analysis for Oral
Anticoagulants by Geographic Region/ Country - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-69

Table 5: World Long-term Projections for Oral Anticoagulants
by Geographic Region/Country - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-70

Table 6: World 10-Year Perspective for Oral Anticoagulants by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-71

Table 7: World Recent Past, Current & Future Analysis for
Injectable Anticoagulants by Geographic Region/Country - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-72

Table 8: World Long-term Projections for Injectable
Anticoagulants by Geographic Region/Country - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-73

Table 9: World 10-Year Perspective for Injectable
Anticoagulants by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Japan, Europe, and Rest of
World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-74

Table 10: World Recent Past, Current & Future Analysis for
Injectable Anticoagulants by Product Segment - Unfractionated
Heparin and Low Molecular Weight Heparin Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-75

Table 11: World Long-term Projections for Injectable
Anticoagulants by Product Segment - Unfractionated Heparin and
Low Molecular Weight Heparin Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-75

Table 12: World 10-Year Perspective for Injectable
Anticoagulants by Product Segment - Percentage Breakdown of
Dollar Sales for Unfractionated Heparin and Low Molecular
Weight Heparin Markets for the Years 2003, 2008 & 2012 II-76

Table 13: World Recent Past, Current & Future Analysis for
Unfractionated Heparin by Geographic Region/Country - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-77

Table 14: World Long-term Projections for Unfractionated
Heparin by Geographic Region/Country - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-78

Table 15: World 10-Year Perspective for Unfractionated Heparin
by Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-79

Table 16: World Recent Past, Current & Future Analysis for Low
Molecular Weight Heparin s by Geographic Region/Country - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-80

Table 17: World Long-term Projections for Low Molecular Weight
Heparin by Geographic Region / Country - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) II-81

Table 18: World 10-Year Perspective for Low Molecular Weight
Heparin by Geographic Region/Country - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World Markets
for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-82


III. MARKET

1. The United States III-1
A. Market Overview III-1
Outlook III-1
Atrial Fibrillation - A Key Risk Factor III-1
Regulatory Route to the US Market III-1
Price Controls III-2
US Anticoagulants Market III-2
US Heparin Market III-2
Hinging on Market Opportunities III-3
Generics - Threatening Branded Anticoagulants III-3
List of Patent Protected Anticoagulants in the US III-4
Ignorance - A Major Hindrance III-4
Future Challenges and Growth Drivers III-4
US Emerging Anticoagulant Market III-4
US Emerging Anticoagulants Market: Products in the Pipeline III-5
Product Introductions III-5
Strategic Corporate Developments III-7
Focus on Select Players III-10
B.Market Analytics III-12
Table 19: US Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-12

Table 20: US Long-term Projections for Anticoagulants by
Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-12

Table 21: US 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-13

2. Japan III-14
A. Market Overview III-14
Pharmaceutical Industry in Japan III-14
Regulatory Procedure in Japan III-14
Drug Pricing in Japan III-14
Anticoagulants Market in Japan III-15
Rising Incidence of Pulmonary Thromboembolism III-15
Product Introductions III-15
Strategic Corporate Developments III-16
Mitsubishi Tanabe Pharma Corporation - A Major Player III-16
B.Market Analytics III-17
Table 22: Japanese Recent Past, Current & Future Analysis
for Anticoagulants by Product Segment - Oral Anticoagulants
and Injectable Anticoagulants (Unfractionated Heparin and
Low Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-17

Table 23: Japanese Long-term Projections for Anticoagulants
by Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-18

Table 24: Japanese 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-19

3. Europe III-20
A. Market Overview III-20
An Analysis of Major Regional Markets III-20
France - A Major Market III-20
UK - High Growth Potential Market III-20
Pharmaceutical Industry in Europe III-20
Regulatory Procedure in Europe III-20
Anticoagulants Market in Europe III-21
List of Patent Protected Anticoagulants in Europe III-21
Injectable Sector - Booming Ahead III-21
Market in High Need of an Ideal Therapy III-21
Product Introductions III-22
Strategic Corporate Development III-22
B.Market Analytics III-23
Table 25: European Recent Past, Current & Future Analysis
for Anticoagulants by Geographic Region/Country - France,
Germany, Italy, UK, Spain, and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-23

Table 26: European Long-term Projections for Anticoagulants
by Geographic Region/Country - France, Germany, Italy, UK,
Spain, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-24

Table 27: European 10-Year Perspective for Anticoagulants by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-25

Table 28: European Recent Past, Current & Future Analysis
for Anticoagulants by Product Segment - Oral Anticoagulants
and Injectable Anticoagulants (Unfractionated Heparin and
Low Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-26

Table 29: European Long-term Projections for Anticoagulants
by Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-27

Table 30: European 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-27

3a. France III-28
A. Market Overview III-28
Sanofi-Aventis - A Major Player III-28
B.Market Analytics III-29
Table 31: French Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-29

Table 32: French Long-term Projections for Anticoagulants by
Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-30

Table 33: French 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-30

3b. Germany III-31
A. Market Overview III-31
Market Drivers for Injectable Anticoagulants III-31
Anticoagulants Growth Drive European POC Testing Market III-31
Strategic Corporate Developments III-31
B.Market Analytics III-32
Table 34: German Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-32

Table 35: German Long-term Projections for Anticoagulants by
Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-33

Table 36: German 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-34

3c. Italy III-35
Market Analysis III-35
Table 37: Italian Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-35

Table 38: Italian Long-term Projections for Anticoagulants
by Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-36

Table 39: Italian 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-36

3d. The United Kingdom III-37
A. Market Overview III-37
Outlook III-37
Growing AF Market for Warfarin III-37
Select Players III-37
Strategic Corporate Developments III-38
B.Market Analytics III-39
Table 40: UK Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-39

Table 41: UK Long-term Projections for Anticoagulants by
Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-40

Table 42: UK 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-41

3e. Spain III-42
Market Analysis III-42
Table 43: Spanish Recent Past, Current & Future Analysis for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-42

Table 44: Spanish Long-term Projections for Anticoagulants
by Product Segment - Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-43

Table 45: Spanish 10-Year Perspective for Anticoagulants by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Anticoagulants and Injectable Anticoagulants
(Unfractionated Heparin and Low Molecular Weight Heparin)
Markets for the Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-44

3f. Rest of Europe III-45
Market Analysis III-45
Table 46: Rest of Europe Recent Past, Current & Future
Analysis for Anticoagulants by Product Segment - Oral
Anticoagulants and Injectable Anticoagulants (Unfractionated
Heparin and Low Molecular Weight Heparin) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-45

Table 47: Rest of Europe Long-term Projections for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-46

Table 48: Rest of Europe 10-Year Perspective for
Anticoagulants by Product Segment - Percentage Breakdown of
Dollar Sales for Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets for the Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) III-47

4. Rest of World III-48
A. Market Overview III-48
Anticoagulants Market in Australia III-48
Strategic Corporate Developments III-48
B.Market Analytics III-49
Table 49: Rest of World Recent Past, Current & Future
Analysis for Anticoagulants by Product Segment - Oral
Anticoagulants and Injectable Anticoagulants (Unfractionated
Heparin and Low Molecular Weight Heparin) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-49

Table 50: Rest of World Long-term Projections for
Anticoagulants by Product Segment - Oral Anticoagulants and
Injectable Anticoagulants (Unfractionated Heparin and Low
Molecular Weight Heparin) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-50

Table 51: Rest of World 10-Year Perspective for
Anticoagulants by Product Segment - Percentage Breakdown of
Dollar Sales for Oral Anticoagulants and Injectable
Anticoagulants (Unfractionated Heparin and Low Molecular
Weight Heparin) Markets for the Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) III-51


IV. COMPETITIVE LANDSCAPE


-Abbott India Limited (India)
-Akers Biosciences, Inc (USA)
-Archemix Corporation (USA)
-Argatroban (USA)
-Aryx Therapeutics, Inc (USA)
-AstraZeneca PLC (UK)
-Astrazeneca Pharmaceuticals LP (USA)
-Barr Laboratories, Inc (USA)
-Bayer HealthCare AG (Germany)
-Boehringer Ingelheim GmbH (Germany)
-Bristol-Myers Squibb Company (USA)
-Bristol-Myers Squibb De Mexico S de RL de CV (Mexico)
-Cardinal Health, Inc (USA)
-Cipla Ltd (India)
-Daiichi Sankyo Co, Limited (Japan)
-Dendreon Corporation (USA)
-DSM Pharmaceuticals (USA)
-Encysive Pharmaceuticals, Inc (USA)
-GlaxoSmithKline PLC (UK)
-Goldshield Pharmaceuticals Ltd (UK)
-GTC Biotherapeutics, Inc (USA)
-Kamada Ltd (Israel)
-Leo Laboratories Ltd (Ireland)
-Merck KGaA (Germany)
-Mitsubishi Pharma Corporation (Japan)
-Mitsubishi Pharma Europe Ltd (UK)
-Momenta Pharmaceuticals, Inc (USA)
-Nabi Biopharmaceuticals (USA)
-Novartis AG (Switzerland)
-Novo Nordisk A/S (Denmark)
-Novo Nordisk Pharma GmbH (Germany)
-Zymogenetics, Inc (USA)
-Nuvelo, Inc (USA)
-Organon International, Inc (USA)
-Pfizer, Inc (USA)
-PharmaNetics, Inc (USA)
-Pharmion Corporation (USA)
-Portola Pharmaceuticals, Inc (USA)
-Progen Industries Ltd (Australia)
-Regado Biosciences, Inc (USA)
-Roche Diagnostics (Schweiz)
AG (Switzerland)
-Sanofi-Aventis (France)
-Shanghai Raas Blood Products Co, Ltd (China)
-Strides Arcolabs Limited (India)
-Taro Pharmaceutical Industries Ltd (Israel)
-Taro Pharmaceuticals USA, Inc (USA)
-Taro Pharmaceuticals, Inc (Canada)
-Taro pharmaceuticals Ltd (UK)
-Teva Pharmaceutical Industries Ltd (Israel)
-The Medicines Company (USA)
-Transtech Pharma, Inc (USA)
-Trigen Ltd (UK)
-Trinity Biotech Plc (Ireland)